Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Novartis ' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a "very difficult situation" and the reality will soon catch up with both drugmakers and patients. "The longer-term implications are significant," CEO Vas Narasimhan told CNBC's Carolin Roth . "The reality of MFN is going to set in in the next 18 months." Novartis is focused on getting European and Japanese governments to quickly change how they reward innovation, he said, adding that if this …